Why I Think Pfizer Is a Better Buy Than Merck & Co.
Pfizer's products and pipeline opportunity may give it an edge over Merck.
Pfizer (NYSE:PFE) and Merck & Co. (NYSE:MRK) are two of the biggest drugmakers on the planet, and both of these companies reward investors with a healthy dividend yield. But I believe it's Pfizer, not Merck, that ought to be in an investor's portfolio.
Here's why...
Source: The Motley Fool